UNSPSC 51202304: Penicillamine disulfide

This classification denotes an angiogenesis activator inhibitor with the molecular formula C10H20N2O4S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q98FPI4N5P, chemically known as d-valine, 3,3'-dithiobis-, but more generally known as penicillamine disulfide, which bears US NIH Compound Identifier 88724. European Medicines Agency schedules penicillamine disulfide or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09667MIG.

Most nations, for tariff purposes, schedule penicillamine disulfide under HS 29309016. SMILES: CC(C)([C@H](C(=O)O)N)SSC(C)(C)[C@H](C(=O)O)N.

UNSPSC 51202304 Penicillamine disulfide is a Commodity code that does not align with the state and local procurement activity currently posted under it. The three most recent opportunities — a Seminole County, Florida procurement for naloxone and drug deactivation systems, a Texas Health and Human Services Commission request for information on direct-to-manufacturer prescription programs, and a Minnesota Multistate Cooperative Purchasing Alliance RFP for generic multi-source pharmaceuticals and OTC products — all address pharmaceutical supply, distribution, and program administration rather than the specific active pharmaceutical ingredient or chelating agent that the code nominally describes. The mismatch suggests that state and local procurement systems are either tagging pharmacy-related solicitations to a narrow ingredient code by error or that the code is being used as a catch-all for pharmaceutical procurement activity that spans multiple NDCs, formulations, and therapeutic categories.

Recent state and local activity shows pharmaceutical procurement driven by multistate cooperative purchasing vehicles and health agencies seeking to manage costs and ensure supply chain compliance. The Minnesota MMCAP RFP, with proposals due March 26, 2026, exemplifies the scale and complexity: it requires vendors to supply generic multi-source pharmaceuticals and OTC products through authorized wholesalers, maintain cGMP and DSCSA certification, carry $5 million in commercial general liability coverage, and accept a 3 percent administrative fee, with contract performance penalties ranging from $200 to $1,500 per violation. Seminole County's IFB for naloxone and drug deactivation systems (due July 26, 2023) sought annual delivery of 1,900 units of naloxone and 800 deactivation systems on a two-year term with one-year renewal option and FEMA-funding compliance requirements. Texas HHS's RFI on direct-to-manufacturer prescriptions signals emerging state interest in bypassing traditional pharmacy benefit managers and wholesalers. Geographic activity centers on Minnesota (through MMCAP's multi-state reach including Oregon), Florida, and Texas, with cooperative purchasing models dominating the procurement approach.